GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-clinical-stage-biopharmaceutical-company-affinivax-inc/